MedTrace Logo

Vaccine Therapy in Treating Patients With Stage IV Melanoma

NCT00023647 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2012-07-10

No results posted yet for this study

Summary

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Infusing the vaccine directly into a lymph node may cause a stronger immune response and kill more tumor cells.

PURPOSE: Phase I trial to study the effectiveness of vaccine therapy given directly into a lymph node in treating patients who have stage IV melanoma.

Conditions

  • Melanoma (Skin)

Interventions

BIOLOGICAL

Synchrotope TA2M

Cancer Vaccine, Immunotherapy

BIOLOGICAL

Synchrotope TA2M

Cancer Vaccine, Immunotherapy

BIOLOGICAL

Synchrotope TA2M

Cancer Vaccine, Immunotherapy

Sponsors & Collaborators

  • Mannkind Corporation

    lead INDUSTRY

Principal Investigators

  • Barbara Hickingbottom, JD, MD · Mannkind Corporation

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-07-31
Primary Completion
2002-04-30
Completion
2002-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00023647 on ClinicalTrials.gov